Results The mAST/AST ratio for patients when they first entered hospital was in the following order: severe hepatitis 0 375±0 073, alcoholic hepatitis 0 311±0 048, chronic hepatitis 0 307±0 039, acute hepatitis 0 302±0 046, drug hepatitis 0 295±0 030, hepatitis cirrhosis 0 276±0 049;
Methods The radioimmunoassaywas usedtodetect the levels of plasma ET-1, serum hyaluronic acid (HA), laminin(LN), type Ⅲ procollagen(PⅢP) and collagen type IV(Ⅳ-C) in 23 cases with acute hepatitis B , 81 cases with chronichepatitis B and 64 cases with posthepatitic cirrhosis .
The levelsof ET-1,HA, LN, PⅢP and Ⅳ-Cincreased as the degree of liver damage progressed inpatients with chronic hepatitis B. The level of plasma ET-1 was not only related to the levels of serum HA,LN,PⅢP and Ⅳ-C, but also to the width of portal vein inpatients withchronic hepatitis B and posthepatitic cirrhosis .
Antibodies against three oligopeptides from the core region of HCV(CP9,CP10,CP14) were detected in 148 patients with chronic liver diseases and primary hepatocellular carcinoma(PHC). The positive rates of these antibodies were 7.7%, 23.1%,23.5% and 16.3% in cases of chronic persistent hepatitis(CPH),chronic active hepatitis(CAH),hepatitis liver cirrhosis(HLC)and PHC respectively.
We also found that sTRAIL level was positively correlated with GGT and ALP concentrations in PBC patients (r=0.63,0.71,P<0.01), but not with those in patients with chronic hepatitis and cirrhosis (r=0.43,0.31,P>0.05).
Results The decrease rate of CHE and PTA in the group of acute hepatitis was 0.00% and 8.82% respectively. The level of serum CHE and PTA decreased gradually in acute hepatitis, chronic hepatitis and cirrhosis(P< 0.01). The correlation coefficient between serum CHE and PTA was 0.752(P< 0.01).